Published online Jan 26, 2019. doi: 10.4252/wjsc.v11.i1.44
Peer-review started: October 29, 2018
First decision: November 29, 2018
Revised: December 6, 2018
Accepted: January 5, 2019
Article in press: January 6, 2019
Published online: January 26, 2019
Pluripotent stem cell (PSC)-derived cardiomyocytes (CMs) have become one of the most attractive cellular resources for cell-based therapy to rescue damaged cardiac tissue.
The proliferative capacity of PSC-derived CMs is decreased after beating and terminal differentiation. Furthermore, there is no definite surface marker of differentiated PSC-derived CMs to facilitate purification.
We investigated the regenerative potential of mouse embryonic stem cell-derived PDGFRα+ cardiac lineage-committed cells (CLCs) in a murine myocardial infarction (MI) model and compared their efficacy with differentiated CMs.
We implanted platelet-derived growth factor receptor-α (PDGFRα)+ CLCs and differentiated αMHC+ CMs into a MI murine model and performed functional analysis using transthoracic echocardiography (TTE) and histologic analysis.
Compared with the untreated MI hearts, the anterior and septal regional wall motion and systolic functional parameters were notably and similarly improved in the MI hearts implanted with PDGFRα+ CLCs and αMHC+ CMs based on TTE. In histologic analysis, the untreated MI hearts contained a thinner ventricular wall than did the controls, while the ventricular walls of MI hearts implanted with PDGFRα+ CLCs and αMHC+ CMs were similarly thicker compared with that of the untreated MI hearts. Furthermore, implanted PDGFRα+ CLCs aligned and integrated with host CMs and were mostly differentiated into α-actinin+ CMs, and they did not convert into CD31+ endothelial cells or αSMA+ mural cells.
PDGFRα+ CLCs from mouse ESCs exhibiting proliferative capacity showed a regenerative effect in infarcted myocardium. Therefore, mouse ESC-derived PDGFRα+ CLCs may represent a potential cellular resource for cardiac regeneration.
PDGFRα+ CLCs served as the potential donor population for cardiac regeneration, and our findings provide conceptual and technical advances in stem cell therapy for cardiac regeneration.